MedPath

Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience

Recruiting
Conditions
Neoplasms, Embryonal
Embryonal Neoplasms
Registration Number
NCT02665676
Lead Sponsor
Assiut University
Brief Summary

The aim of this study is to investigate demographic \& disease characteristics of pediatric cancer patients diagnosed with one of embryonal tumors to identify the prevalence, the spectrum of these disease entities \& treatment outcomes in these patients.

Detailed Description

Background:

Embryonal tumors arise from cells that are normally present in the developing embryo and originate in developing tissues and organ systems. These tumors occur almost exclusively in children, and are usually diagnosed in children before age 5 years.

The group is heterogeneous and includes relatively common pediatric tumors as well as rare tumors. Three common types of embryonal tumors in children are neuroblastoma, Wilms tumor (WT), and retinoblastoma. Other embryonal tumors, include medulloblastoma and rhabdomyosarcoma.

Patients \& Methods:

From January 2001 to December 2015, retrieval \& analysis of the medical records of pediatric patients with embryonal tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
420
Inclusion Criteria
  • Patients whose age less than or equal to 18 years.
  • Patients diagnosed with any of embryonal neoplasms.
Exclusion Criteria

• Patients whose age more than 18 years.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival (OS)Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years

Time from the date of initiation of treatment until death from any cause

Event Free Survival (EFS)Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years

Time from the date of initiation of treatment until disease progression, or death for any reason

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Assiut University

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath